TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12427142

Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa (administered at a reduced dose frequency)
Number of subjects: 522

Group type: COMPARATOR
Intervention: rHuEPO (administered at standard frequency)
Number of subjects: 522

Group type: COMPARATOR
Intervention: Comparison of darbepoetin alfa and rHuEPO
Number of subjects: 522

Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa and rHuEPO
Number of subjects: 522
Study: 10520780

Group type: EXPERIMENTAL
Intervention: Low-level exercise echocardiography (LLEE)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Low-dose dobutamine echocardiography (LDDE)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Follow-up echocardiography
Number of subjects: 52
Study: 8866632

Group type: COMPARATOR
Intervention: 400 mg PROP
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 600 mg PROP
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 400 mg PROP + 100 mg CAFF
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 600 mg PROP + 150 mg CAFF
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 1727457

Group type: EXPERIMENTAL
Intervention: Interactive videodisc preparation
Number of subjects: 35

Group type: COMPARATOR
Intervention: Noninteractive videotape preparation
Number of subjects: 35

Group type: COMPARATOR
Intervention: Surgeon-only consultation
Number of subjects: 35
Study: 6369216

Group type: EXPERIMENTAL
Intervention: BSS Plus with glucose = 400 mg/dl
Number of subjects: 20

Group type: COMPARATOR
Intervention: BSS Plus with glucose = 100 mg/dl
Number of subjects: 20
Study: 31475320

Group type: EXPERIMENTAL
Intervention: Immediate laparoscopic cholecystectomy (LC)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Same admission delayed laparoscopic cholecystectomy (LC)
Number of subjects: 64
Study: 28647788

Group type: EXPERIMENTAL
Intervention: 10 mg IV-dexamethasone (group dexa)
Number of subjects: 110

Group type: COMPARATOR
Intervention: IV-isotonic saline (group placebo)
Number of subjects: 110
Study: 27149585

Group type: EXPERIMENTAL
Intervention: WSEB exercises (3 times per week, 40 minutes per session for 6 months)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 138
Study: 25471761

Group type: EXPERIMENTAL
Intervention: Individualised pelvic floor muscle training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 22622275

Group type: EXPERIMENTAL
Intervention: EMDR
Number of subjects: 20

Group type: COMPARATOR
Intervention: CBT
Number of subjects: 20
Study: 20514986

Group type: EXPERIMENTAL
Intervention: MCPs-treated diabetics
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: MCPs-treated diabetics with hypertension
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo-treated diabetics
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo-treated diabetics with hypertension
Number of subjects: 200
Study: 17506593

Group type: EXPERIMENTAL
Intervention: Doxazosin 4 mg/day
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Amlodipine 10 mg/day
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (healthy controls)
Number of subjects: 38
Study: 16242593

Group type: EXPERIMENTAL
Intervention: Water gargling
Number of subjects: 387

Group type: EXPERIMENTAL
Intervention: Povidone-iodine gargling
Number of subjects: 387

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 387
Study: 12072903

Group type: EXPERIMENTAL
Intervention: ATG Fresenius
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Thymoglobulin Mérieux
Number of subjects: 50
Study: 10086537

Group type: EXPERIMENTAL
Intervention: Synthetic calcitonin (40 Medical Research Council Standard Units subcutaneously per day in 14-day cycles)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo preparation
Number of subjects: 61
Study: 7672156

Group type: EXPERIMENTAL
Intervention: T undecanoate (40 mg three times per day)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: TAM (10 mg two times per day)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: hMG (75 IU/d)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: T undecanoate and TAM
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: T undecanoate and hMG
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 1796127

Group type: EXPERIMENTAL
Intervention: Dependence Index (DI) measured at 48 hours, 4 weeks, and 8 weeks post-cessation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Craving measure obtained 48 hours after smoking cessation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dependence Index (DI)
Number of subjects: 0
Study: 6347779

Group type: EXPERIMENTAL
Intervention: Interruption of continuous subcutaneous insulin infusion
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Insulin supplements administered via the pump after resetting at basal rate
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control test with the pump functioning normally
Number of subjects: 8
Study: 30382712

Group type: EXPERIMENTAL
Intervention: BRIGHTEN Heart team intervention plus membership in Generations
Number of subjects: 250

Group type: COMPARATOR
Intervention: Generations only (comparison group)
Number of subjects: 250
Study: 28895568

Group type: EXPERIMENTAL
Intervention: Targeted cognitive training (TCT) for 40 hours
Number of subjects: 44

Group type: COMPARATOR
Intervention: Computer games control (CG)
Number of subjects: 44
Study: 26648386

Group type: COMPARATOR
Intervention: Panoramic imaging (non-scan group)
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Cone Beam CT (CBCT) (scan group)
Number of subjects: 230
Study: 24809408

Group type: EXPERIMENTAL
Intervention: Oral glutamine (GL) supplementation for 7 days
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 22382187

Group type: EXPERIMENTAL
Intervention: Thrice-daily biphasic human insulin (30/70, BHI)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Basal detemir and bolus aspart (BB)
Number of subjects: 50
Study: 20003492

Group type: EXPERIMENTAL
Intervention: Cross-curricular physical activity intervention (2 hours a week for 18 weeks, brisk walking 3200 m twice weekly during curriculum lessons)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 0
Study: 17143004

Group type: EXPERIMENTAL
Intervention: Cognitive flexibility
Number of subjects: 63

Group type: COMPARATOR
Intervention: Age, quadriceps strength of the paretic side, current physical activity level
Number of subjects: 63
Study: 15886447

Group type: EXPERIMENTAL
Intervention: Regularity Index 1 (RI1) in back pain patients
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Regularity Index 2 (RI2) in back pain patients
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Gait information flow characteristics in back pain patients
Number of subjects: 21

Group type: COMPARATOR
Intervention: Regularity Indices (RI1 and RI2)
Number of subjects: 21
Study: 12032542

Group type: EXPERIMENTAL
Intervention: Mid-day nap between the second and third sessions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Shifting target stimuli to an untrained region of visual space
Number of subjects: 0

Group type: COMPARATOR
Intervention: Repeated within-day testing without intervention
Number of subjects: 0
Study: 10623052

Group type: EXPERIMENTAL
Intervention: Enhanced access to primary care
Number of subjects: 443

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 443
Study: 7875757

Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 26

Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 26
Study: 2193979

Group type: EXPERIMENTAL
Intervention: 150 mg ranitidine (half dose)
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: 300 mg ranitidine (full dose)
Number of subjects: 139
Study: 7471920

Group type: EXPERIMENTAL
Intervention: SMART program
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: PUSH program
Number of subjects: 56

Group type: COMPARATOR
Intervention: Standard Reading group
Number of subjects: 56

Group type: COMPARATOR
Intervention: Nonintervention group
Number of subjects: 56
Study: 30834817

Group type: EXPERIMENTAL
Intervention: Interactive decision tool intervention for FTASD treatment
Number of subjects: 200

Group type: COMPARATOR
Intervention: Text-based control on shoulder dislocations and treatments
Number of subjects: 200
Study: 27921445

Group type: EXPERIMENTAL
Intervention: MJ-exposed infants
Number of subjects: 1867

Group type: COMPARATOR
Intervention: MJ-unexposed infants
Number of subjects: 1867
Study: 25833773

Group type: EXPERIMENTAL
Intervention: Whey protein supplementation (20 g/d)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Gelatin protein supplementation
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Both whey and gelatin groups
Number of subjects: 27

Group type: COMPARATOR
Intervention: Whey protein vs. Gelatin protein
Number of subjects: 27
Study: 23890573

Group type: EXPERIMENTAL
Intervention: Triple-antiplatelet therapy (TAT; aspirin, clopidogrel, and cilostazol)
Number of subjects: 1399

Group type: COMPARATOR
Intervention: Dual-antiplatelet therapy (aspirin and clopidogrel)
Number of subjects: 1399
Study: 22174434

Group type: EXPERIMENTAL
Intervention: Exemestane
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Letrozole
Number of subjects: 0
Study: 19619377

Group type: EXPERIMENTAL
Intervention: Phone-based, nurse-led educational, care coordination palliative care intervention model, provided weekly for the first month and then monthly until death, including bereavement follow-up call to the caregiver.
Number of subjects: 279

Group type: COMPARATOR
Intervention: Care as usual (control group).
Number of subjects: 279
Study: 17502727

Group type: EXPERIMENTAL
Intervention: Antiretroviral drug resistance
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Multi-class resistance
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: CXCR4-using HIV-1 strains
Number of subjects: 195
Study: 15478000

Group type: EXPERIMENTAL
Intervention: Risedronate (5 mg daily)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 11125189

Group type: EXPERIMENTAL
Intervention: Cavitated lesions
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Lesions >0.5 mm from the enamel‐dentine junction
Number of subjects: 54

Group type: COMPARATOR
Intervention: Non-cavitated lesions
Number of subjects: 54
Study: 9676346

Group type: EXPERIMENTAL
Intervention: 350 mg sustained release theophylline (Bronchoretard) administered in a fasting state
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 350 mg sustained release theophylline (Bronchoretard) administered after a standard meal
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 350 mg sustained release theophylline (Bronchoretard) administered after a high-caloric fat evening meal
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Co-administration of food with theophylline
Number of subjects: 18
Study: 7734463

Group type: EXPERIMENTAL
Intervention: Enhanced clinical services (more frequent and intensive group therapy, or adding individual treatment services)
Number of subjects: 303

Group type: COMPARATOR
Intervention: Standard group therapy treatment program
Number of subjects: 303
Study: 3057924

Group type: EXPERIMENTAL
Intervention: Imipramine as an adjunct to fluphenazine decanoate and benztropine regimens
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo as an adjunct to fluphenazine decanoate and benztropine regimens
Number of subjects: 46
Study: 1124176

Group type: EXPERIMENTAL
Intervention: Tetracycline (1000 patients)
Number of subjects: 4000

Group type: COMPARATOR
Intervention: Control (2000 patients)
Number of subjects: 4000
Study: 30808389

Group type: EXPERIMENTAL
Intervention: Smartphone cessation app (Just Kwit!)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (patient-initiated follow up)
Number of subjects: 0
Study: 28592288

Group type: EXPERIMENTAL
Intervention: Maternal recall of stool frequency
Number of subjects: 0

Group type: COMPARATOR
Intervention: Direct observation using diapers (gold standard)
Number of subjects: 0
Study: 25119509

Group type: EXPERIMENTAL
Intervention: Multidisciplinary treatment with psychomotor therapy (PMT)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Multidisciplinary treatment as usual without PMT
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Multidisciplinary treatment with PMT
Number of subjects: 94
Study: 22812594

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention
Number of subjects: 2766

Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 2766

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2766
Study: 21293087

Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil (OM) 20 mg for 4 weeks, then OM 40 mg for 4 weeks (n = 420)
Number of subjects: 941

Group type: COMPARATOR
Intervention: Losartan potassium (LOS) 50 mg for 4 weeks, then LOS 100 mg for 4 weeks (n = 469)
Number of subjects: 941

Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil (OM)
Number of subjects: 941

Group type: COMPARATOR
Intervention: Losartan potassium (LOS)
Number of subjects: 941
Study: 18607729

Group type: EXPERIMENTAL
Intervention: Current smokers
Number of subjects: 430

Group type: COMPARATOR
Intervention: Anxiety caseness
Number of subjects: 430
Study: 17135808

Group type: EXPERIMENTAL
Intervention: In-clinic behavioral assessment
Number of subjects: 644

Group type: COMPARATOR
Intervention: Telephonic administration of the same assessment
Number of subjects: 644

Group type: EXPERIMENTAL
Intervention: Behavioral measures of depression, anxiety, irritability, and apathy
Number of subjects: 644
Study: 12923410

Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil (8-16 mg once daily)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Hydrochlorothiazide (HCTZ, 25-50 mg once daily)
Number of subjects: 127
Study: 11194516

Group type: EXPERIMENTAL
Intervention: p-HES (1000 ml)
Number of subjects: 20

Group type: COMPARATOR
Intervention: c-HES (1000 ml)
Number of subjects: 20
Study: 9527698

Group type: EXPERIMENTAL
Intervention: Medical interventions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quality of life scales
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: N-of-1 trial
Number of subjects: 0
Study: 8417271

Group type: EXPERIMENTAL
Intervention: Usual care plus a hospital-based smoking-cessation intervention
Number of subjects: 1119

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1119
Study: 3565455

Group type: EXPERIMENTAL
Intervention: Native intravenous immunoglobulin (IVIG)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Modified intravenous immunoglobulin (IVIG)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Native IVIG
Number of subjects: 10

Group type: COMPARATOR
Intervention: Modified IVIG
Number of subjects: 10
Study: 30471072

Group type: EXPERIMENTAL
Intervention: BPLN® (a mix of bioactive substances including a donor of nitric oxide, magnesium, and vitamins)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 27696918

Group type: EXPERIMENTAL
Intervention: EMDR‐RE
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Delayed EMDR‐RE
Number of subjects: 60

Group type: COMPARATOR
Intervention: CISD
Number of subjects: 60
Study: 23683800

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (30 mg of daily zinc sulfate)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo (same shape and color as zinc)
Number of subjects: 64
Study: 22277061

Group type: EXPERIMENTAL
Intervention: Joint action condition (2 models acting together)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Individual action condition (2 models acting individually)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Solitary action condition (1 model acting alone)
Number of subjects: 48
Study: 20556817

Group type: EXPERIMENTAL
Intervention: ERB-041 (5 mg)
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: ERB-041 (25 mg)
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: ERB-041 (75 mg)
Number of subjects: 291

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 291
Study: 18508226

Group type: EXPERIMENTAL
Intervention: Tigecycline (TGC) 100 mg followed by 50 mg bid
Number of subjects: 846

Group type: EXPERIMENTAL
Intervention: Tigecycline (TGC)
Number of subjects: 846

Group type: COMPARATOR
Intervention: Levofloxacin (LEV) 500 mg bid
Number of subjects: 846

Group type: COMPARATOR
Intervention: Levofloxacin (LEV)
Number of subjects: 846
Study: 17029520

Group type: EXPERIMENTAL
Intervention: Transbond XT (Group 1)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Fluoride-releasing adhesive (Kurasper F) (Group 2)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Antimicrobial self-etching primer (Clearfil Protect Bond) + Fluoride-releasing adhesive (Group 3)
Number of subjects: 120
Study: 15281191

Group type: EXPERIMENTAL
Intervention: Sad mood induction in state-oriented participants
Number of subjects: 0

Group type: COMPARATOR
Intervention: Participants able to downregulate negative affect (action-oriented participants)
Number of subjects: 0
Study: 11083963

Group type: EXPERIMENTAL
Intervention: Nebulized ipratropium bromide (250 mg per dose) plus nebulized salbutamol (0.2 mg/kg) and oral steroids (1 mg/kg)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo plus nebulized salbutamol (0.2 mg/kg) and oral steroids (1 mg/kg)
Number of subjects: 102
Study: 9387086

Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 62

Group type: COMPARATOR
Intervention: Viloxazine
Number of subjects: 62
Study: 8466016

Group type: EXPERIMENTAL
Intervention: Intramuscular injection at vastus lateralis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Subcutaneous injection at vastus lateralis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intramuscular injection at deltoid
Number of subjects: 0

Group type: COMPARATOR
Intervention: Subcutaneous injection at deltoid
Number of subjects: 0
Study: 3083913

Group type: EXPERIMENTAL
Intervention: Enprostil 35 micrograms twice daily
Number of subjects: 180

Group type: COMPARATOR
Intervention: Ranitidine 150 mg twice daily
Number of subjects: 180
Study: 31557375

Group type: EXPERIMENTAL
Intervention: Compassion-inducing images
Number of subjects: 327

Group type: COMPARATOR
Intervention: Neutral images (control)
Number of subjects: 327
Study: 29578604

Group type: EXPERIMENTAL
Intervention: Lay health educator intervention
Number of subjects: 504

Group type: EXPERIMENTAL
Intervention: Knowledge of CRC screening guidelines
Number of subjects: 504

Group type: EXPERIMENTAL
Intervention: Patient-provider ethnicity concordance and provider's recommendation of screening
Number of subjects: 504

Group type: EXPERIMENTAL
Intervention: Prior CRC screening
Number of subjects: 504

Group type: EXPERIMENTAL
Intervention: Perceived severity and susceptibility of CRC
Number of subjects: 504

Group type: EXPERIMENTAL
Intervention: Knowledge of guidelines
Number of subjects: 504
Study: 26551446

Group type: EXPERIMENTAL
Intervention: H5N1(2) - H5N1 group (2-dose priming with A/Indonesia/05/2005-H5N1-AS03B followed by booster with A/turkey/Turkey/1/2005-H5N1-AS03B)
Number of subjects: 0

Group type: COMPARATOR
Intervention: HAV-H5N1 group (single dose of A/turkey/Turkey/1/2005-H5N1-AS03B in unprimed subjects)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: H5N1(2) - H5N1 group
Number of subjects: 0
Study: 24791022

Group type: EXPERIMENTAL
Intervention: Tdap vaccination during intervention period
Number of subjects: 1530

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 1530
Study: 22787172

Group type: EXPERIMENTAL
Intervention: Soy milk
Number of subjects: 25

Group type: COMPARATOR
Intervention: Cow's milk
Number of subjects: 25
Study: 19952063

Group type: EXPERIMENTAL
Intervention: NTHi oral immunotherapeutic (HI‐164OV)
Number of subjects: 38
Study: 17363355

Group type: EXPERIMENTAL
Intervention: Online haemodiafiltration
Number of subjects: 76

Group type: COMPARATOR
Intervention: High-flux haemodialysis
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Both high-flux haemodialysis and online haemodiafiltration
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Both groups (online haemodiafiltration and high-flux haemodialysis)
Number of subjects: 76
Study: 15353020

Group type: EXPERIMENTAL
Intervention: Lymphdiaral (Pascoe, Giessen, Germany)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Chronic tonsillitis nosode at a C3 potency (Spagyra, Grödig, Austria)
Number of subjects: 32
Study: 11607900

Group type: EXPERIMENTAL
Intervention: Indwelling catheter
Number of subjects: 99

Group type: COMPARATOR
Intervention: Intermittent catheterization
Number of subjects: 99
Study: 9535583

Group type: EXPERIMENTAL
Intervention: 10 x 400 m interval running workouts with recovery durations of 180 s
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 10 x 400 m interval running workouts with recovery durations of 120 s
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 10 x 400 m interval running workouts with recovery durations of 60 s
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 10 x 400 m interval running workouts (averaged across conditions)
Number of subjects: 12
Study: 8009573

Group type: EXPERIMENTAL
Intervention: IR verapamil, 80 mg t.i.d. (Phase B)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: SR verapamil, 240 mg q.d. (Phase C)
Number of subjects: 12

Group type: COMPARATOR
Intervention: IR propranolol, 160 mg (Phase A)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Combined verapamil groups (Phase B and C)
Number of subjects: 12
Study: 2605788

Group type: EXPERIMENTAL
Intervention: Naloxone (4 mg bolus and 6 mg/h)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 6
Study: 15756556

Group type: EXPERIMENTAL
Intervention: EMLA creme applied before upper lid blepharoplasty
Number of subjects: 14

Group type: COMPARATOR
Intervention: Non-treated side (Control)
Number of subjects: 14
Study: 31680496

Group type: EXPERIMENTAL
Intervention: Propofol (group P)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (group D)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ketofol (group K)
Number of subjects: 60
Study: 31430032

Group type: EXPERIMENTAL
Intervention: Balanced stress outcomes
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Positive stress outcomes
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Negative stress outcomes
Number of subjects: 77

Group type: COMPARATOR
Intervention: Control
Number of subjects: 77
Study: 27676631

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment (up to 20 treatments within 6 months)
Number of subjects: 209

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 209